Reuters: Regulatory News: UPDATE 1-Novartis psoriasis drug superior to Enbrel in study

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Novartis psoriasis drug superior to Enbrel in study Jul 8th 2013, 12:47 Mon Jul 8, 2013 8:47am EDT * Secukinumab more effective than Enbrel in head-to-head study * Novartis expects to file for approval in second half of 2013 * Market for psoriasis drugs to double to $7.6 bln by 2022 - analyst ZURICH, July 8 (Reuters) - Novartis psoriasis drug secukinumab was superior to Amgen's Enbrel in a late-stage study, the Swiss company said on Monday, putting it in line to become the first of a clutch of new treatments to gain market approval. A phase III trial involving 1,307 patients showed that secukinumab was more effective than Enbrel in clearing skin in patients with moderate to severe plaque-type psoriasis, a painful and unsightly skin condition that causes itching and scaling. Novartis said it expects to present full results of the study later in the year and that it is on track to file for regulatory approval by the end of the year. "These results, showing that secukinumab is superior to Enbrel, a current standard-of-care therapy, are great news for people living with moderate to severe plaque psoriasis," said Tim Wright, global head of development at Novartis. Plaque psoriasis is thought to be caused by an inflammatory response initiated by the body's immune system and affects about 125 million people. Those suffering from the disease are also at a greater risk of developing diabetes and heart disease. Novartis is among a pack of drugmakers developing new treatments for psoriasis, including Eli Lilly, AstraZeneca, Celgene and Amgen. Analysts at Citi expect a flood of new treatments to help to more than double sales in the psoriasis market to $7.6 billion by 2022, from $3.6 billion in 2012. Kepler Chevreux analysts forecast peak sales of $701 million in 2020. Shares in Novartis were trading up by almost 1.5 percent at 68.60 Swiss francs ($71.18) by 1240 GMT, against a 1 percent rise for the European healthcare index. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions